Newly-Diagnosed or Advanced HER2-Expressing Gastroesophageal Adenocarcinomas
Gastroesophageal adenocarcinomas (GEAs) are cancers that begin in the stomach (gastric), esophagus, and/or and gastroesophageal junction. Stomach cancer is the fifth most common malignancy worldwide with over a million new cases per year1.
GEAs are approximately 20 times more prevalent in Eastern Asia than in North America. Nearly 18 percent of GEAs are positive for human epidermal growth factor receptor 2, or HER2, which means they make too much of this protein2. Too much HER2 protein may cause cancer to grow more quickly and spread to other parts of the body3.
Today’s standard treatments for GEAs include surgery, radiation, chemotherapy, targeted therapy, and immunotherapy4. Zymeworks is currently conducting clinical trials to test new potential targeted treatments for this disease.
- World Health Organization GLOBOCAN 2018 Stomach Fact Sheet
- Custem EV et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015; 18:476–484.
- NIH National Cancer Institute: NCI Dictionary of Cancer Terms
- NIH National Cancer Institute: Gastric Cancer Treatment (PDQ®)–Patient Version
There are no trials currently running.